Avanos (AVNS) Q4 2025 earnings review
Core Segments Grow, But Tariffs and Divestitures Squeeze the Bottom Line
Avanos delivered a mixed finish to 2025. While top-line Q4 net sales grew 0.7% YoY (absorbing the heavy drag of the HA product line divestiture), profitability took a significant hit. Adjusted diluted EPS dropped 33% YoY to $0.29, and Free Cash Flow collapsed to $21.3M from $53.1M. The underlying story is a tug-of-war: the Specialty Nutrition Systems (SNS) segment continues to post excellent volume growth, but gross margins are buckling under the weight of tariffs and manufacturing shifts. Management is aggressively targeting $15-$20M in annualized savings by 2026, but the FY26 guidance ($0.90-$1.10 EPS on flat/low-growth sales) signals that the turnaround will be a slow grind rather than a quick snapback.
🐂 Bull Case
The Specialty Nutrition Systems segment grew 8.7% YoY in Q4 to $115.1M. It consistently outperforms the market, fueled by strong volume in enteral feeding and neonate solutions.
Pain Management & Recovery broke out of its slump. Sales grew 1.3% YoY in Q4, and more importantly, operating income for the segment jumped 33% (from $3.9M to $5.2M), proving that the Radiofrequency Ablation (RFA) momentum is real.
🐻 Bear Case
Despite 8.7% sales growth, SNS operating income plunged 18% YoY to $20.5M in Q4. When your fastest-growing, highest-margin segment shows negative operating leverage, it raises immediate red flags about underlying costs.
Q4 Free Cash Flow plummeted 60% YoY to $21.3M. For the full year, FCF was nearly halved ($43.1M vs $82.9M). The cash drain limits Avanos's flexibility for M&A, which is a key pillar of their transformation strategy.
⚖️ Verdict: ⚪
Neutral. Avanos is successfully pruning its portfolio (exiting HA products) and growing its core SNS business. However, the inability to translate that top-line success into bottom-line margin expansion due to persistent tariff headwinds keeps the stock in 'show-me' territory.
Key Themes
Negative Operating Leverage in SNS Segment
A crucial data point contradicts the positive volume narrative in the Specialty Nutrition Systems (SNS) segment. In Q4, SNS net sales increased by $9.2M (+8.7% YoY), yet operating income fell by $4.5M (-18.0% YoY). This means the segment's operating margin compressed violently from 23.6% in 24Q4 to 17.8% in 25Q4. This suggests that tariff absorption, mix shifts, or higher input costs are overriding the benefits of volume growth.
Cost Optimization Targets Expanded
To combat margin degradation, Avanos expanded its transformation initiatives. Management explicitly targeted $15 million to $20 million of incremental annualized savings by the end of 2026. This will be critical to offsetting the structural tariff costs and accelerating the exit from China-sourced NeoMed products.
Persistent Macro Headwind: Tariffs
Tariffs (primarily related to China and Mexico sourcing) remain the primary drag on Avanos's profitability. Throughout 2025, management cited tariffs as the core reason for lowered EPS expectations. While mitigation efforts (like moving syringe manufacturing out of China) are underway, the timeline stretches into mid-2026, leaving margins exposed in the interim.
Radiofrequency Ablation (RFA) Momentum
Within the PM&R segment, RFA technology is proving to be a durable bright spot. RFA sales grew 8.2% YoY in Q4 to $36.9M and finished the year up 10.1%. This growth offsets the persistent weakness in the Surgical Pain and Recovery sub-segment (down 7.5% in Q4), stabilizing the overall PM&R portfolio.
Portfolio Pruning Completed
The 'Corporate and Other' segment saw sales drop 67.4% YoY in Q4 (to $4.2M), entirely driven by the July 2025 divestiture of the low-growth, pricing-pressured Hyaluronic Acid (HA) product line. While this hurts consolidated top-line growth optically, it completes a necessary shedding of dead weight, allowing capital to be reallocated toward the SNS segment.
Collapsing Free Cash Flow Trajectory
The company's ability to generate cash deteriorated sharply as the year progressed. Q4 Free Cash Flow fell to $21.3M from $53.1M a year ago. For the full year, FCF printed at $43.1M, a steep deceleration from $82.9M in 2024. This is a direct consequence of higher Capital Expenditures ($31.6M vs $17.8M) to restructure the supply chain, combined with weaker operating profit.
Other KPIs
Decelerating. A severe drop from 58.7% in Q4 2024. For the full year, adjusted gross margin contracted to 54.6% from 59.0% in 2024. This 440-basis-point annual compression is the clearest evidence of the pricing pressures and tariff impacts plaguing the cost of goods sold.
Decelerating. Down from $107.6 million in 2024. Despite lower Adjusted SG&A expenses in Q4 ($70.8M vs $74.8M), the absolute gross profit decline dragged down the full-year EBITDA.
Improving. Avanos maintained excellent balance sheet health, ending the year with $89.8M in cash against $100.5M in term loan borrowings. Net debt shrank from $27.0M a year ago, keeping leverage extremely low and preserving dry powder for future bolt-on M&A.
Guidance
Stable. The midpoint of $710M represents a nominal 1.2% growth over FY25 ($701.2M). While optically slow, this figure must be viewed in the context of the HA divestiture, which provided 7 months of revenue in FY25 that will not repeat in FY26. The underlying organic growth of SNS and PM&R is expected to be higher.
Accelerating slightly. The midpoint of $1.00 implies a 6.4% YoY growth from FY25's $0.94. Achieving this will rely heavily on the execution of the new $15-$20M cost savings program, given the expected flatness in top-line reported sales.
Key Questions
SNS Margin Walk
SNS sales grew 8.7% but operating profit fell 18% in Q4. Could you bridge this margin compression? How much of this is structural (tariffs) versus timing or temporary product mix shifts?
Cost Savings Execution Risk
You are targeting $15-$20M in incremental annualized savings by the end of 2026. Given the ongoing supply chain transitions, what is the expected cadence of these savings hitting the P&L throughout 2026?
Capital Allocation Following Divestitures
With the HA divestiture complete and net debt sitting at a very low $10.7M, what is the appetite for deploying the balance sheet toward M&A in the near term to accelerate the SNS growth engine?